Prospective study evaluating the safety, efficacy, and pharmacokinetics of ledipasvir/sofosbuvir for 8, 12 or 24 weeks in patients with HCV infection on dialysis
Latest Information Update: 16 Sep 2019
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 16 Sep 2019 New trial record